In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 3, 2014, Pages 1774-1778

  Wang, Xiaojuan ^a   Zhang, Feifei ^a   Zhao, Chunjiang ^a   Wang, Zhanwei ^a   Nichols, Wright W ^b   Testa, Raymond ^b   Li, Henan ^a   Chen, Hongbin ^a   He, Wenqiang ^a   Wang, Qi ^a   Wang, Hui ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM; AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; CEFTAZIDIME; MEROPENEM;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CHINA; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; TEACHING HOSPITAL;

AZABICYCLO COMPOUNDS; AZTREONAM; BETA-LACTAMASES; CEFTAZIDIME; CHINA; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITALS, TEACHING; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84896832898     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02123-13     Document Type: Article

References (19)

1. Ehmann DE, Jahić H, Ross PL, Gu RF, Hu J, Kern G, Walkup GK, Fisher SL. 2012. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc. Natl. Acad. Sci. U. S. A. 109:11663-11668. http://dx.doi.org/10.1073/pnas.1205073109.
2. Coleman K. 2011. Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors. Curr. Opin. Microbiol. 14:550-555. http://dx.doi.org/10.1016/j.mib.2011.07.026.
3. Shlaes DM. 2013. New β-lactam-β-lactamase inhibitor combinations in clinical development. Ann. N. Y. Acad. Sci. 1277:105-114. http://dx.doi.org/10.1111/nyas.12010.
4. Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagacé-Wiens PR, Denisuik A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP, III, Karlowsky JA. 2013. Ceftazidime-avibactam: a novel cephalosporin/β- lactamase inhibitor combination. Drugs 73:159-177. http://dx.doi.org/10.1007/ s40265-013-0013-7.
5. Sader HS, Flamm RK, Jones RN. 2013. Antimicrobial activity of ceftaroline-avibactam tested against clinical isolates collected from U.S. medical centers in 2010-2011. Antimicrob. Agents Chemother. 57:1982-1988. http://dx.doi.org/10.1128/AAC.02436-12.
6. Stachyra T, Levasseur P, Péchereau MC, Girard AM, Claudon M, Miossec C, Black MT. 2009. In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J. Antimicrob. Chemother. 64:326-329. http://dx.doi.org/10.1093/ jac/dkp197.
7. Endimiani A, Choudhary Y, Bonomo RA. 2009. In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob. Agents Chemother. 53:3599-3601. http://dx.doi.org/10.1128/AAC.00641-09.
8. Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, Woodford N. 2011. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 55:390-394. http://dx.doi.org/10.1128/AAC.00756-10.
9. Lagacé-Wiens PR, Tailor F, Simner P, DeCorby M, Karlowsky JA, Walkty A, Hoban DJ, Zhanel GG. 2011. Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases. Antimicrob. Agents Chemother. 55:2434-2437. http://dx.doi.org/10.1128/AAC.01722-10.
10. Aktas Z, Kayacan C, Oncul O. 2012. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Int. J. Antimicrob. Agents. 39:86-89. http://dx.doi.org/10.1016/j.ijantimicag.2011.09. 012.
11. Crandon JL, Nicolau DP. 2013. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging Gram-negative organisms, including metallo-β-lactamase producers. Antimicrob. Agents Chemother. 57:3299-3306. http://dx.doi.org/10.1128/AAC.01989-12.
12. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M7-A9, 9th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing: 23rd informational supplement. M100-S23. Clinical and Laboratory Standards, Wayne, PA.
14. Queenan AM, Bush K. 2007. Carbapenemases: the versatile beta-lactamases. Clin. Microbiol. Rev. 20:440-458. http://dx.doi.org/10.1128/CMR.00001-07.
15. Sanders CC. 1987. Chromosomal cephalosporinases responsible for multiple resistance to newer β-lactam antibiotics. Annu. Rev. Microbiol. 41: 573-593. http://dx.doi.org/10.1146/annurev.mi.41.100187.003041.
16. Pfaller MA, Jones RN, Marshall SA, Coffman SL, Hollis RJ, Edmond MB, Wenzel RP. 1997. Inducible ampC β-lactamase producing Gram-negative bacilli from bloodstream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). Diagn. Microbiol. Infect. Dis. 28:211-219. (Pubitemid 27425219)
17. Poirel L, Guibert M, Girlich D, Naas T, Nordmann P. 1999. Cloning, sequence analyses, expression, and distribution of ampC-ampR from Morganella morganii clinical isolates. Antimicrob. Agents Chemother. 43:769-776. (Pubitemid 29165738)
18. Walkty A, DeCorby M, Lagacé-Wiens PRS, Karlowsky JA, Hoban DJ, Zhanell GG. 2011. In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals: CANWARD 2009. Antimicrob. Agents Chemother. 55: 2992-2994. http://dx.doi.org/10. 1128/AAC.01696-10.
19. Levasseur P, Girard A-M, Claudon M, Goossens H, Black MT, Coleman K, Miossec C. 2012. In vitro antibacterial activity of the ceftazidimeavibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 56:1606-1608. http://dx.doi.org/10.1128/AAC.06064- 11.